Latest news with #PrurigoNodularis
Globe and Mail
04-04-2025
- Health
- Globe and Mail
Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therapeutics
The Key Prurigo Nodularis Companies in the market include - Trevi Therapeutics, Galderma, Genentech, Incyte Corporation, Vyne Therapeutics Inc., Celgene Corporation, Novartis, Pfizer, Regeneron Pharma, and others. DelveInsight's 'Prurigo Nodularis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Prurigo Nodularis, historical and forecasted epidemiology as well as the Prurigo Nodularis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. Some of the key facts of the Prurigo Nodularis Market Report: The Prurigo Nodularis market size is anticipated to grow with a significant CAGR during the study period (2020-2034) In March 2025, Incyte (Nasdaq: INCY) announced findings from its pivotal Phase 3 TRuE-PN clinical trial program, including the TRuE-PN1 and TRuE-PN2 studies, assessing the safety and efficacy of twice-daily ruxolitinib cream 1.5% (Opzelura®), a topical JAK1/2 inhibitor, in adult patients (18 years and older) with prurigo nodularis (PN). In March 2025, Incyte (Nasdaq: INCY) announced positive topline results from its pivotal Phase 3 STOP-HS trial assessing the safety and efficacy of povorcitinib (INCB054707), an oral JAK1 inhibitor, in adults (≥18 years) with moderate to severe hidradenitis suppurativa (HS). Povorcitinib, a selective JAK1 inhibitor, is also being investigated in Phase 3 trials for vitiligo and prurigo nodularis (PN) and in Phase 2 trials for asthma and chronic spontaneous urticaria (CSU). In February 2025, Galderma (SWX:GALD) announced that the European Commission has granted approval for Nemluvio in the EU to treat both moderate-to-severe atopic dermatitis and prurigo nodularis. Nemluvio is now authorized for subcutaneous use in patients aged 12 and older with moderate-to-severe atopic dermatitis requiring systemic therapy, as well as in adults with moderate-to-severe prurigo nodularis eligible for systemic treatment. According to Morgan et al. (2022), the estimated prevalence of prurigo nodularis was recorded at 3.27 cases per 10,000 patients. In 2023, among the 7MM, the United States had the largest diagnosed prevalent population of prurigo nodularis. As per estimates, in Europe, the highest prevalence of age-specific cases of prurigo nodularis was observed in the 40-59 years age group, representing over 30% of the total cases in 2023. DUPIXENT (dupilumab) stands as the sole therapeutic approved by the US FDA for the treatment of prurigo nodularis, with several other treatments currently undergoing development. Key Prurigo Nodularis Companies: Trevi Therapeutics, Galderma, Genentech, Incyte Corporation, Vyne Therapeutics Inc., Celgene Corporation, Novartis, Pfizer, Regeneron Pharma, and others Key Prurigo Nodularis Therapies: Nalbuphine ER, Nemolizumab, Vixarelimab(KPL-716), Povorcitinib(INCB-54707), Ruxolitinib Cream, INCB054707, serlopitant, CC-10004, Pimecrolimus, Abrocitinib, Dupilumab SAR231893, and others The Prurigo Nodularis epidemiology based on gender analyzed that females are affected more as compared to males, in the case of Prurigo Nodularis The Prurigo Nodularis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Prurigo Nodularis pipeline products will significantly revolutionize the Prurigo Nodularis market dynamics. Prurigo Nodularis Overview Prurigo nodularis is a chronic skin condition characterized by the development of intensely itchy nodules or bumps on the skin. These nodules can vary in size and color and often appear on the arms, legs, or trunk. The itching associated with prurigo nodularis can be severe and persistent, leading to scratching and potentially causing further irritation and skin damage. The exact cause of prurigo nodularis is not fully understood, but it is believed to involve a combination of factors such as underlying skin conditions, nerve dysfunction, and immune system abnormalities. Get a Free sample for the Prurigo Nodularis Market Report Prurigo Nodularis Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Prurigo Nodularis Epidemiology Segmentation: The Prurigo Nodularis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Download the report to understand which factors are driving Prurigo Nodularis epidemiology trends @ Prurigo Nodularis Epidemiology Forecast Prurigo Nodularis Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Prurigo Nodularis market or expected to get launched during the study period. The analysis covers Prurigo Nodularis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Prurigo Nodularis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Prurigo Nodularis Therapies and Key Companies Discover more about therapies set to grab major Prurigo Nodularis market share @ Prurigo Nodularis Treatment Market Prurigo Nodularis Market Strengths Novel drug formulations are unlocking the new market outlook and the potential to improve the QoL of patients suffering from the serious symptoms associated with chronic neurologically mediated conditions for which there are few, if any, treatment options. Vixarelimab's dual mechanism offers potential pruritus relief and nodule improvement in prurigo nodularis. Prurigo Nodularis Market Opportunities Increasing population gives a lucrative opportunity to increase the awareness and innovation of therapeutics to drive the prurigo nodularis market. Due to one approved drug in the market, there is a huge opportunity for the companies who are coming with novel emerging therapies. Scope of the Prurigo Nodularis Market Report Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Prurigo Nodularis Companies: Trevi Therapeutics, Galderma, Genentech, Incyte Corporation, Vyne Therapeutics Inc., Celgene Corporation, Novartis, Pfizer, Regeneron Pharma, and others Key Prurigo Nodularis Therapies: Nalbuphine ER, Nemolizumab, Vixarelimab(KPL-716), Povorcitinib(INCB-54707), Ruxolitinib Cream, INCB054707, serlopitant, CC-10004, Pimecrolimus, Abrocitinib, Dupilumab SAR231893, and others Prurigo Nodularis Therapeutic Assessment: Prurigo Nodularis current marketed and Prurigo Nodularis emerging therapies Prurigo Nodularis Market Dynamics: Prurigo Nodularis market drivers and Prurigo Nodularis market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Prurigo Nodularis Unmet Needs, KOL's views, Analyst's views, Prurigo Nodularis Market Access and Reimbursement Table of Contents 1. Prurigo Nodularis Market Report Introduction 2. Executive Summary for Prurigo Nodularis 3. SWOT analysis of Prurigo Nodularis 4. Prurigo Nodularis Patient Share (%) Overview at a Glance 5. Prurigo Nodularis Market Overview at a Glance 6. Prurigo Nodularis Disease Background and Overview 7. Prurigo Nodularis Epidemiology and Patient Population 8. Country-Specific Patient Population of Prurigo Nodularis 9. Prurigo Nodularis Current Treatment and Medical Practices 10. Prurigo Nodularis Unmet Needs 11. Prurigo Nodularis Emerging Therapies 12. Prurigo Nodularis Market Outlook 13. Country-Wise Prurigo Nodularis Market Analysis (2020–2034) 14. Prurigo Nodularis Market Access and Reimbursement of Therapies 15. Prurigo Nodularis Market Drivers 16. Prurigo Nodularis Market Barriers 17. Prurigo Nodularis Appendix 18. Prurigo Nodularis Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
Globe and Mail
11-03-2025
- Health
- Globe and Mail
Prurigo Nodularis Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, NDA Approvals, Medication, Prevalence, MOA, Revenue, Statistics and Companies by DelveInsight
Prurigo Nodularis Companies are Trevi Therapeutics, Galderma, Genentech, Incyte Corporation, Vyne Therapeutics Inc., Celgene Corporation, Novartis, Pfizer, Regeneron Pharma, and others. (Albany, USA) DelveInsight's ' Prurigo Nodularis Market Insights, Epidemiology, and Market Forecast-2034 ″ report offers an in-depth understanding of the Prurigo Nodularis, historical and forecasted epidemiology as well as the Prurigo Nodularis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The Prurigo Nodularis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Prurigo Nodularis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Prurigo Nodularis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Prurigo Nodularis market. Some of the key facts of the Prurigo Nodularis Market Report: The Prurigo Nodularis market size is anticipated to grow with a significant CAGR during the study period (2020-2034) In March 2025, Incyte (Nasdaq:INCY) announced results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and TRuE-PN2 studies – evaluating the safety and efficacy of twice-daily ruxolitinib cream 1.5% (Opzelura®), a topical JAK1/2 inhibitor, in adult patients (≥18 years) with prurigo nodularis (PN). The positive TRuE-PN1 data were presented as a late-breaking oral presentation (Session: S028 – Late-Breaking Research: Session 1) today at the 2025 American Academy of Dermatology (AAD) Annual Meeting, being held March 7–11, 2025, in Orlando. In February 2025, Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedic have granted the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the UK and Switzerland, respectively. Specifically, the approvals are for nemolizumab's subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors in adults and adolescents 12 years of age and older with a body weight of at least 30kg, who are candidates for systemic therapy, and for subcutaneous use for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. In August 2024, Galderma has announced that the U.S. Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) as a pre-filled pen for subcutaneous injection to treat adults with prurigo nodularis. Nemluvio received Breakthrough Therapy Designation in December 2019 and Priority Review in February 2024, highlighting its potential to significantly enhance treatment for serious conditions. In March 2024, Incyte revealed recently released late-breaking data from a Phase II study assessing povorcitinib in individuals diagnosed with prurigo nodularis. According to Morgan et al. (2022), the estimated prevalence of prurigo nodularis was recorded at 3.27 cases per 10,000 patients. In 2023, among the 7MM, the United States had the largest diagnosed prevalent population of prurigo nodularis. DUPIXENT (dupilumab) stands as the sole therapeutic approved by the US FDA for the treatment of prurigo nodularis, with several other treatments currently undergoing development. Key Prurigo Nodularis Companies: Trevi Therapeutics, Galderma, Genentech, Incyte Corporation, Vyne Therapeutics Inc., Celgene Corporation, Novartis, Pfizer, Regeneron Pharma, and others Key Prurigo Nodularis Therapies: Nalbuphine ER, Nemolizumab, Vixarelimab(KPL-716), Povorcitinib(INCB-54707), Ruxolitinib Cream, INCB054707, serlopitant, CC-10004, Pimecrolimus, Abrocitinib, Dupilumab SAR231893, and others The Prurigo Nodularis epidemiology based on gender analyzed that females are affected more as compared to males, in the case of Prurigo Nodularis The Prurigo Nodularis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Prurigo Nodularis pipeline products will significantly revolutionize the Prurigo Nodularis market dynamics. Prurigo Nodularis Overview Prurigo Nodularis (PN) is a chronic inflammatory skin disorder characterized by the presence of multiple, intensely itchy, firm nodules that develop due to prolonged scratching and skin trauma. The exact cause of Prurigo Nodularis remains unclear, but it is associated with immune system dysregulation, chronic pruritus, nerve abnormalities, and underlying conditions such as atopic dermatitis, diabetes, chronic kidney disease, HIV, and psychiatric disorders. Prurigo Nodularis Patients experience severe, persistent pruritus (itching), often leading to excoriated, hyperpigmented, or lichenified nodules that typically affect the arms, legs, and trunk. The itch-scratch cycle worsens the condition, making it difficult to treat. Prurigo Nodularis significantly impacts quality of life, causing sleep disturbances, anxiety, depression, and social embarrassment. Prurigo Nodularis Diagnosis is clinical, based on the characteristic nodules and patient history, but may require skin biopsies, blood tests, or nerve function assessments to rule out underlying conditions. Treatment focuses on breaking the itch-scratch cycle using topical corticosteroids, calcineurin inhibitors, antihistamines, and emollients. In severe cases, biologic therapies (such as IL-31 inhibitors), immunosuppressants, gabapentinoids, and phototherapy may be needed. Recent advancements in targeted biologics and neuromodulators are improving outcomes, offering new hope for long-term disease control and symptom relief in Prurigo Nodularis patients. Prurigo Nodularis Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Prurigo Nodularis Epidemiology Segmentation: The Prurigo Nodularis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalence of Prurigo Nodularis Prevalent Cases of Prurigo Nodularis by severity Gender-specific Prevalence of Prurigo Nodularis Diagnosed Cases of Episodic and Chronic Prurigo Nodularis Download the report to understand which factors are driving Prurigo Nodularis epidemiology trends @ Prurigo Nodularis Epidemiology Forecast Prurigo Nodularis Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Prurigo Nodularis market or expected to get launched during the study period. The analysis covers Prurigo Nodularis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Prurigo Nodularis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Prurigo Nodularis Therapies and Key Companies Nalbuphine ER: Trevi Therapeutics Nemolizumab: Galderma Vixarelimab(KPL-716): Genentech Povorcitinib(INCB-54707): Incyte Corporation Ruxolitinib Cream: Incyte Corporation INCB054707: Incyte Corporation serlopitant: Vyne Therapeutics Inc. CC-10004: Celgene Corporation Pimecrolimus: Novartis Abrocitinib: Pfizer Dupilumab SAR231893: Regeneron Pharma Discover more about therapies set to grab major Prurigo Nodularis market share @ Prurigo Nodularis Treatment Market Prurigo Nodularis Market Strengths Novel drug formulations are unlocking the new market outlook and the potential to improve the QoL of patients suffering from the serious symptoms associated with chronic neurologically mediated conditions for which there are few, if any, treatment options. Vixarelimab's dual mechanism offers potential pruritus relief and nodule improvement in prurigo nodularis. Prurigo Nodularis Market Opportunities Increasing population gives a lucrative opportunity to increase the awareness and innovation of therapeutics to drive the prurigo nodularis market. Due to one approved drug in the market, there is a huge opportunity for the companies who are coming with novel emerging therapies. Scope of the Prurigo Nodularis Market Report Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Prurigo Nodularis Companies: Trevi Therapeutics, Galderma, Genentech, Incyte Corporation, Vyne Therapeutics Inc., Celgene Corporation, Novartis, Pfizer, Regeneron Pharma, and others Key Prurigo Nodularis Therapies: Nalbuphine ER, Nemolizumab, Vixarelimab(KPL-716), Povorcitinib(INCB-54707), Ruxolitinib Cream, INCB054707, serlopitant, CC-10004, Pimecrolimus, Abrocitinib, Dupilumab SAR231893, and others Prurigo Nodularis Therapeutic Assessment: Prurigo Nodularis current marketed and Prurigo Nodularis emerging therapies Prurigo Nodularis Market Dynamics: Prurigo Nodularis market drivers and Prurigo Nodularis market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Prurigo Nodularis Unmet Needs, KOL's views, Analyst's views, Prurigo Nodularis Market Access and Reimbursement To know more about Prurigo Nodularis companies working in the treatment market, visit @ P rurigo Nodularis Clinical Trials and Therapeutic Assessment Table of Contents 1. Prurigo Nodularis Market Report Introduction 2. Executive Summary for Prurigo Nodularis 3. SWOT analysis of Prurigo Nodularis 4. Prurigo Nodularis Patient Share (%) Overview at a Glance 5. Prurigo Nodularis Market Overview at a Glance 6. Prurigo Nodularis Disease Background and Overview 7. Prurigo Nodularis Epidemiology and Patient Population 8. Country-Specific Patient Population of Prurigo Nodularis 9. Prurigo Nodularis Current Treatment and Medical Practices 10. Prurigo Nodularis Unmet Needs 11. Prurigo Nodularis Emerging Therapies 12. Prurigo Nodularis Market Outlook 13. Country-Wise Prurigo Nodularis Market Analysis (2020–2034) 14. Prurigo Nodularis Market Access and Reimbursement of Therapies 15. Prurigo Nodularis Market Drivers 16. Prurigo Nodularis Market Barriers 17. Prurigo Nodularis Appendix 18. Prurigo Nodularis Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
Yahoo
28-02-2025
- Business
- Yahoo
Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting
- Featured abstracts for ruxolitinib cream (Opzelura®) include multiple presentations in atopic dermatitis and late-breaking data in prurigo nodularis (PN) - Pipeline data presented includes data for axatilimab (Niktimvo™) in patients with dermatologic manifestations of chronic graft-versus-host disease (GVHD) WILMINGTON, Del., February 28, 2025--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) today announced that multiple abstracts featuring new data from its dermatology portfolio will be presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting, being held March 7–11, 2025, in Orlando. "We look forward to sharing new data for ruxolitinib cream (Opzelura®) across multiple indications, including prurigo nodularis, and axatilimab (Niktimvo™) in patients with dermatologic manifestations of chronic graft-versus-host disease (GVHD) at this year's AAD Annual Meeting," said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. "Incyte's active participation in this key congress reinforces our commitment to addressing critical needs in dermatology while fostering meaningful dialogue with researchers, patients and advocates to inform the development of innovative treatments." Key abstracts include: Late-Breaking Oral Presentation Prurigo Nodularis (PN) Efficacy and Safety of Ruxolitinib Cream in Patients With Prurigo Nodularis: Results From a Phase 3, Randomized, Vehicle-Controlled Study (TRuE-PN1)(Session: S028 – Late-Breaking Research: Session 1. Saturday, March 8, 2025, 9:24 a.m. ET) ePoster Exhibits Atopic Dermatitis (AD) Long-Term Safety of Ruxolitinib Cream in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Adverse Events of Interest from the TRuE-AD1 and TRuE-AD2 Phase 3 Studies (Abstract: #64524) Association of Ruxolitinib Cream Initiation with Reduction in Use of Other Topical Treatments, Oral Corticosteroids, and Biologics for Atopic Dermatitis, Regardless of Previous Use of Biologics (Abstract: #64526) 52-Week Disease Control and Safety with As-Needed Application of Ruxolitinib Cream in Children Aged 2 to 11 Years with Moderate and/or More Extensive Atopic Dermatitis: Subgroup Analysis from the TRuE-AD3 Study (Abstract: #64656) Ruxolitinib Cream Demonstrated Long-Term Disease Control and Quality of Life Benefits in Adults and Adolescents with Mild to Moderate Atopic Dermatitis (Abstract: #64727) Graft-Versus-Host Disease (GVHD) Axatilimab for Patients with Dermatologic Manifestations of Chronic Graft-Versus-Host Disease: A Post Hoc Analysis (Abstract: #64616) More information regarding the 2025 AAD Annual Meeting can be found at: About Opzelura® (ruxolitinib) Cream 1.5%Opzelura, a novel cream formulation of Incyte's selective JAK1/JAK2 inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older, is the first and only treatment for repigmentation approved for use in the United States. Opzelura is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Use of Opzelura in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants, such as azathioprine or cyclosporine, is not recommended. In Europe, Opzelura (ruxolitinib) cream 15mg/g is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. Incyte has worldwide rights for the development and commercialization of ruxolitinib cream, marketed in the United States as Opzelura. Opzelura and the Opzelura logo are registered trademarks of Incyte. About Niktimvo™ (axatilimab-csfr)Niktimvo (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (88.2 lbs). In 2016, Syndax licensed exclusive worldwide rights to develop and commercialize axatilimab from UCB. In September 2021, Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement for axatilimab in chronic GVHD and any future indications. Axatilimab is being studied in frontline combination trials in chronic GVHD – a Phase 2 combination trial with ruxolitinib (NCT06388564) and a Phase 3 combination trial with steroids (NCT06585774) are underway. Axatilimab is also being studied in an ongoing Phase 2 trial in patients with idiopathic pulmonary fibrosis (NCT06132256). Niktimvo is a trademark of Incyte. All other trademarks are the property of their respective owners. About Povorcitinib (INCB54707)Povorcitinib (INCB54707) is an oral small-molecule JAK1 inhibitor currently in Phase 3 clinical trials for vitiligo, hidradenitis suppurativa (HS) and prurigo nodularis (PN), as well as Phase 2 trials for asthma and chronic spontaneous urticaria (CSU). About IncyteA global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For additional information on Incyte, please visit or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube. Incyte Forward-Looking StatementsExcept for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from Incyte's clinical development pipeline, whether or when any development compounds or combinations will be approved or commercially available for use in humans anywhere in the world outside of the already approved indications in specific regions, and Incyte's goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on Incyte's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA, EMA, and other regulatory authorities; the efficacy or safety of Incyte and its partners' products; the acceptance of Incyte and its partners' products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in Incyte's reports filed with the Securities and Exchange Commission, including its annual report on form 10-K for the year ended December 31, 2024. Incyte disclaims any intent or obligation to update these forward-looking statements. View source version on Contacts Media media@ Investors ir@
